转移性三阴性乳腺癌的系统治疗:当前的治疗方法和未来的方向
Laura Morrison1, Alicia Okines1
1Breast Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Cancers
|August 12, 2023
概括
转移性三阴性乳腺癌 (TNBC) 呈现多种亚型,导致新的向疗法,如免疫疗法和抗体药物联合体 (ADC). 这些进展提供了希望,但生存率仍然落后于其他乳腺癌类型.
科学领域:
- 在瘤学瘤学.
- 医学遗传学 医学遗传学
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性三阴性乳腺癌 (TNBC) 在历史上一直被统一地治疗,尽管其生物学复杂.
- 基因表达研究揭示了TNBC的异质性,有四种主要的分子亚型 (基质类型1和2,介质类型,光类安卓受体).
- 以前的全身治疗方案仅限于缓和化疗.
研究的目的:
- 审查目前针对TNBC亚型的向治疗的数据.
- 讨论免疫疗法的作用,抗体药物联合体 (ADC) 和向药物的作用.
- 突出正在进行的临床试验,以推进TNBC治疗.
主要方法:
- 审查科学文献和临床试验数据.
- 对基因表达研究和基于生物标志物的治疗策略的分析.
- 对特定TNBC分子亚型的治疗益处的评估.
主要成果:
- 免疫疗法对PD-L1阳性TNBC是有效的.
- PARP 抑制剂对具有生殖系 BRCA 突变的患者有好处.
- 萨西图祖马布戈维特康 (ADC) 在ER阴性,HER2阴性晚期乳腺癌 (ABC) 中显示有用性.
- 特拉斯图祖马布德鲁克斯泰干 (ADC) 对具有低HER2表达的TNBC有益.
结论:
- 最近的进展包括免疫疗法,ADC和针对特定TNBC亚组的向药物.
- 尽管有进展,但TNBC中位生存率仍然低于ER阳性或HER2阳性乳腺癌.
- 目前正在进行的临床试验旨在进一步改善晚期TNBC患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


